#ATOSS Software’s Q2 2025 revenues grew 9% yoy to EUR 45.8m, again driven by the SaaS business, with revenues from cloud/subscription up 30% yoy. HOLD. research-hub.de

#Traton reported weak Q2 2025 results and cut its outlook. We reiterate SELL. research-hub.de $8TRA #Stocks #Earnings #Investing #TruckMakers #DAX #OutlookCut #Q22025

🚨 $PUM profit warning for FY25 ❌ Sales: –low double-digit ❌ EBIT turns negative: –€157m ❌ Weakness across all regions ⚠️ Downgraded to HOLD, PT €22 Brand relevance under pressure. Can #PUMA bounce back? Full report 👉 research-hub.de #stocks #retail #profitwarning

#Verbio's Q4 FY25 results are expected to show early signs of operational recovery. A full turnaround remains unlikely at this stage but seems on the horizon. BUY. research-hub.de $VBK #Biofuels #Earnings #GreenEnergy #Investing #SmallCaps

#Nordex reported Q2 results above consensus. EBITDA rose significantly, lifting margin to 5.8% (+230bps yoy), supported by favorable market conditions. BUY. research-hub.de $NDX1 #Renewables #Earnings #Investing #WindEnergy

#SUSSMicroTec ($SUSS) delivered a strong Q2 revenue beat but profitability fell short due to higher than expected cost pressure and one-offs. The profit warning offers a buying opportunity, BUY. research-hub.de #stocks #earnings #profitwarning #Semiconductors #SmallCaps

📢 Ahead of TUI’s Q3: Late Easter boost + strong summer bookings support 7.2% rev growth & ~17% EBIT jump YoY. #Cruises, #Hotels & pricing drive margin gains despite cost pressure. BUY reiterated, PT €16. 🌴✈️ #TUI #TravelStocks #Earnings #Tourism #UK #Germany

📊 Dräger Q2 confirmed: Revenue +1.8% YoY (fx-adj.) to €780m, EBIT €20m. Medical shines (+5%), Safety dips (–2%). Orders jump +14.3% to €877m — best Q2 since 2020, led by Medical. Strong backlog supports H2. PT €72.00, HOLD maintained. #Dräger #MedTech #Earnings #Healthcare

🔥 #Siltronic Q2 beat on sales & EBITDA margin 📈 📉 H2 still soft, but 2026 could mark a sharp rebound as demand returns. 💡 Strategic positioning in silicon wafers + high leverage to recovery = compelling setup. ✅ BUY. 🔎 Full view: research-hub.de #Semiconductors

🚨 Heidelberg enters #defense via strategic deal with VINCORION 🔧🛡️ First step beyond print into military-grade power systems. Small near-term impact, but opens a high-margin, growth-rich vertical aligned with EU defense push. 📈 BUY, PT €2.60 #Heidelberg #Defense #Stocks

🚨 TeamViewer Q2: ✅ Revenue +6% ✅ Enterprise +15% ✅ Adj. EBITDA +17% to €84m (44% margin!) 📉 1E weak – H1 below target 📌 FY outlook confirmed, 1E needs H2 boost 💪 Solid ops, cost control on point 📈 #BUY rating, PT €15.50 #Earnings #Stocks #Tech research-hub.de

🚨 Update: @KoenigBauerAG with strong prelim Q2 💥 📈 Sales +7% YoY, offsetting soft Q1 💪 Profitability improving significantly 🔍 Evaluating sale of non-core assets ✅ We reiterate: BUY 👉 research-hub.de #KoenigBauer $SKB #Earnings #ValueStocks #Germany #Industrials

🚀 Solid Q2 from Krones 📦 📊 Revenue €1.32bn (+0.6%), EBITDA €139m (+6.4%) – in line 📝 Orders €1.29bn, backlog €4.29bn 💪 📈 H1: Revenue +6.7%, EBITDA margin 10.6% 🎯 FY guidance confirmed ✅ BUY Full report👉research-hub.de #Krones $KRN #Earnings #Engineering

💊 Redcare Pharmacy Q2🔥 📈 Sales +26.5%, EBITDA +21% 🇩🇪 German Rx +125% 🚀 thanks to CardLink adoption 📅 FY25 guidance confirmed 📲 e-Rx momentum + license extension = LT growth drivers ✅ BUY Full report research-hub.de #Redcare $RDC #eHealth #Pharmacy #GrowthStock

📉 @TAKKT_AG Q2/H1 2025: Weak results, as pre-announced 📦 No short-term demand recovery expected ⚠️ Challenging macro persists ✅ Still rated BUY – long-term potential intact Full report: research-hub.de #TAKKT $TTK #Earnings #IndustrialSupplies #ValueStock #GermanStocks

🖥️ TeamViewer Q2 2025 Update 🔍 📈 Revenue +6%, Adj. EBITDA +17% → 44% margin 💪 💡 Strong cost control 📉 1E segment weak (rev. decline QoQ) 🎯 FY25 outlook confirmed ✅ BUY 👉Full report: research-hub.de #TeamViewer $TMV #TechStocks #Earnings #Software #Growth